Drugs, tales, and other stories

Dunno, mate

BMJ 2007; 335 doi: http://dx.doi.org/10.1136/bmj.39276.621065.34 (Published 19 July 2007)
Cite this as: BMJ 2007;335:160.2

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ike Iheanacho, editor, Drug and Therapeutics Bulletin
  1. iiheanacho{at}bmjgroup.com

    Having produced a new treatment, drug companies take great care to avoid testing it too exhaustively in patients. Now, such an assertion would provoke howls of protest from the drug industry, which would no doubt point out just how much clinical research it does (lots) and contrast this with the amount of non-industry development of new drugs (very little).

    While some of this counter-argument is half true, it doesn't alter the fact that too much essential information about many new drugs is missing when these products …

    Get access to this article and all of bmj.com for the next 14 days

    Sign up for a 14 day free trial today

    Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL